Antidepressant like effect of selective serotonin reuptake inhibitors involve modulation of imidazoline receptors by agmatine

Neuropharmacology

Volumn 57, Issue 4, 2009, Pages 415-424

  Taksande, Brijesh G ^a   Kotagale, Nandkishor R ^a   Tripathi, Sunil J ^a   Ugale, Rajesh R ^a   Chopde, Chandrabhan T ^a  

^a India   (India)

Author keywords

5 HT; Agmatine; Depression; Imidazoline receptors; SSRI

Indexed keywords

2 (2 BENZOFURANYL) 2 IMIDAZOLINE; 2 IMIDAZOLINE DERIVATIVE; AGMATINE; AMINOGUANIDINE; ARCAINE; ARGININE; CLONIDINE; DEXTRO ARGININE; EFAROXAN; EFLORNITHINE; FLUOXETINE; IDAZOXAN; IMIDAZOLINE I2 RECEPTOR; IMIDAZOLINE RECEPTOR; IMIPRAMINE; MOXONIDINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MECHANISM; FORCED SWIMMING TEST; MALE; MOBILIZATION; MOUSE; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; REARING;

AGMATINE; ANIMALS; ANTIDEPRESSIVE AGENTS; ARGININE; BRAIN; CARBOXY-LYASES; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; IMIDAZOLINE RECEPTORS; MALE; MICE; MOTOR ACTIVITY; SEROTONIN UPTAKE INHIBITORS; STRESS, PSYCHOLOGICAL;

EID: 68749114959     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2009.06.035     Document Type: Article

References (107)

1. Abramets I.I., and Dolzhenko A.T. Harman and its derivatives as potential atypical antidepressants. Farmakol Toksikol 49 4 (1986) 15-19
2. Adell A., Biggs T.A., and Myers R.D. Action of harman (1-methyl-beta-carboline) on the brain: body temperature and in vivo efflux of 5-HT from hippocampus of the rat. Neuropharmacology 35 8 (1996) 1101-1107
3. 2 imidazoline-preferring receptors. British Journal of Pharmacology 114 4 (1995) 837-845
4. Aricioglu-Kartal F., and Uzbay I.T. Inhibitory effect of agmatine on naloxone-precipitated abstinence syndrome in morphine dependent rats. Life Sciences 61 (1997) 1775-1781
5. Bence A.K., Worthen D.R., Stables J.P., and Crooks P.A. An in vivo evaluation of the antiseizure activity and acute neurotoxicity of agmatine. Behavioral Brain Research 74 (2003) 771-775
6. 2-site ligands BU 224 and 2-BFI inhibit MAO-A and MAO-B activities, hydrogen peroxide production, and lipolysis in rodent and human adipocytes. European Journal of Pharmacology 552 1-3 (2006) 20-30
7. Bousquet P., Bruban V., Schann S., and Feldman J. Imidazoline receptors: a challenge. Pharmaceutica Acta Helvetiae 74 (2000) 205-209
8. 2 sites. Journal of Pharmacology and Experimental Therapeutics 272 2 (1995) 681-688
9. Cervo L., and Samanin R. Clonidine causes antidepressant-like effects in rats by activating alpha 2-adrenoceptors outside the locus ceruleus. European Journal of Pharmacology 193 3 (1991) 309-313
10. Coleman C.S., Hu G., and Pegg A.E. Putrescine biosynthesis in mammalian tissues. Biochemistry Journal 379 (2004) 849-855
11. De Vos H., Bricca G., De Keyser J., De Backer J.P., Bousquet P., and Vauquelin G. Imidazoline receptors, non-adrenergic idazoxan binding sites and alpha 2-adrenoceptors in the human central nervous system. Neuroscience 59 3 (1994) 589-598
12. Duman E.N., Kesim M., Kadioglu M., Ulku C., Kalyoncu N.I., and Yaris E. Effect of gender on antinociceptive effect of paroxetine in hot plate test in mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry 30 2 (2006) 292-296
13. Eglen R.M., Hudson A.L., Kendall D.A., Nutt D.J., Morgan N.G., and Wilson V.G. 'Seeing through a glass darkly': casting light on imidazoline 'I' sites. Trends in Pharmacological Sciences 19 9 (1998) 381-390
14. Eriksson E., Hedberg M.A., Andersch B., and Sundblad C. The serotonin reuptake inhibitor paroxetine is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology 12 (1995) 167-176
15. Farzin D., and Mansouri N. Antidepressant-like effect of harmane and other beta- carbolines in the mouse forced swim test. European Neuropsychopharmacology 16 5 (2006) 324-328
16. 2 receptor selective ligand BU224 in naive rats and rats exposed to the stress of the forced swim test. Psychopharmacology (Berl) 167 2 (2003) 195-202
17. Garcia-Sevilla J.A., Escriba P.V., Sastre M., Walzer C., Busquets X., and Jaquet G. Immunodetection and quantitation of imidazoline receptor proteins in platelets of patients with major depression and in brains of suicide victims. Archives of General Psychiatry 53 9 (1996) 803-810
18. Garcia-Sevilla J.A., Escriba P.V., Ozaita A., Walzer C., and Guimon J. Density of imidazoline receptors in platelets of euthymic patients with bipolar affective disorder and in brains of lithium-treated rats. Biological Psychiatry 43 (1998) 616-618
19. 2-imidazoline binding sites in positive and negative morphine analgesia modulatory effects. European Journal of Pharmacology 553 (2006) 73-81
20. Gong Z.H., Li Y.F., Zhao N., Yang H.J., Su R.B., Luo Z.P., and Li J. Anxiolytic effect of agmatine in rats and mice. European Journal of Pharmacology 550 (2006) 112-116
21. Gourion D., Perrin E., and Quintin P. Fluoxetine: an update of its use in major depressive disorder in adults. Encephale 30 4 (2004) 392-399
22. Grillo M.A., and Colombatto S. Metabolism and functions in animal tissues of agmatine, a biogenic amine formed from arginine. Amino Acids 26 (2004) 3-8
23. Halaris A., Zhu H., Ali J., Nasrallah A., De Vane C.L., and Piletz J.E. Down-regulation of platelet imidazoline-1-binding sites after bupropion treatment. International Journal of Neuropsychopharmacology 5 1 (2002) 37-46
24. Halaris A., and Piletz J.E. Imidazoline receptors: possible involvement in the pathophysiology and treatment of depression. Human Psychopharmacology 16 (2001) 65-69
25. Hao Y.J., Kitashiba H., Honda C., Nada K., and Moriguchi T. Expression of arginine decarboxylase and ornithine decarboxylase genes in apple cells and stressed shoots. Journal of Experimental Botany 56 (2005) 1105-1115
26. Harkin A., Connor T.J., Walsh M., St John N., and Kelly J.P. Serotonergic mediation of the antidepressant-like effects of nitric oxide synthase inhibitors. Neuropharmacology 44 5 (2003) 616-623
27. Harkin A., Connor T.J., Burns M.P., and Kelly J.P. Nitric oxide synthase inhibitors augment the effects of serotonin re-uptake inhibitors in the forced swimming test. European Neuropsychopharmacology 14 4 (2004) 274-281
28. Hernandez S., and Schwarcz de Tarlovsky S. Arginine decarboxylase in Trypanosoma cruzi, characteristics and kinetic properties. Cellular and Molecular Biology (Noisy-le-grand) 45 (1999) 383-391
29. Hirani K., Khisti R.T., and Chopde C.T. Behavioral actions of ethanol in Porsolt's forced swim test: modulation by 3alpha-hydroxy-5alpha-pregnan-20-one. Neuropharmacology 43 (2002) 1339-1350
30. Holt A. Imidazoline binding sites on receptors and enzymes: emerging targets for novel antidepressant drugs?. Journal of Psychiatry and Neuroscience 28 6 (2003) 409-414
31. Holt A., and Baker G.B. Metabolism of agmatine (clonidine- displacing substance) by diamine oxidase and the possible implications for studies of imidazoline receptors. Progress in Brain Research 106 (1995) 187-197
32. Holt A., and Baker G.B. Inhibition of rat brain monoamine oxidase enzymes by fluoxetine and norfluoxetine. Naunyn Schmiedebergs Archieves of Pharmacology 354 1 (1996) 17-24
33. 15N-labelled arginine. Biochemistry Journal 388 (2005) 419-425
34. Huang M.J., Regunathan S., Botta M., Lee K., McClendonYi G.B., Pedersen M.L., Berkowitz D.B., Wang G., Travagli M., and Piletz J.E. Structure-activity analysis of guanidine group in agmatine for brain agmatinase. Annals of New York Academy of Sciences 1009 (2003) 52-63
35. Inan S.Y., Yalcin I., and Aksu F. Dual effects of nitric oxide in the mouse forced swimming test: possible contribution of nitric oxide-mediated serotonin release and potassium channel modulation. Pharmacology Biochemistry and Behavior 77 (2004) 457-464
36. Iyo A.H., Zhu M.Y., Ordway G.A., and Regunathan S. Expression of arginine decarboxylase in brain regions and neuronal cells. Journal of Neurochemistry 96 (2006) 1042-1050
37. Jones T.Z., Giurato L., Guccione S., and Ramsay R.R. Interactions of imidazoline ligands with the active site of purified monoamine oxidase A. FEBS Journal 274 6 (2007) 1567-1575
38. Kaehler S.T., Singewald N., Sinner C., and Philippu A. Nitric oxide modulates the release of serotonin in the rat hypothalamus. Brain Research 835 (1999) 346-349
39. Kolesnikov Y., Jain S., and Pasternak G.W. Modulation of opioid analgesia by agmatine. European Journal of Pharmacology 296 (1996) 17-22
40. Lavinsky D., Arteni N.S., and Netto C.A. Agmatine induces anxiolysis in the elevated plus maze task in adult rats. Behavioral Brain Research 141 1 (2003) 19-24
41. Li G., Regunathan S., Barrow C.J., Eshraghi J., Cooper R., and Reis D.J. Agmatine: an endogenous clonidine-displacing substance in the brain. Science 263 (1994) 966-969
42. Li G., Regunathan S., and Reis D.J. Agmatine is synthesized by a mitochondrial arginine decarboxylase in rat brain. Annals of New York Academy of Sciences 763 (1995) 325-329
43. Li J., Li X., Pei G., and Qin B.Y. Agmatine inhibited tolerance to and dependence on morphine in guinea pig ileum in vitro. Acta Pharmacologica Sinica 19 (1998) 564-568
44. Li Y.F., Gong Z.H., Cao J.B., Wang H.L., Luo Z.P., and Li J. Antidepressant-like effect of agmatine and its possible mechanism. European Journal of Pharmacology 469 (2003) 81-88
45. Lortie M.J., Novotny W.F., Peterson O.W., Vallon V., Malvey K., Mendonca M., Satriano J., Insel P., Thomson S.C., and Blantz R.C. Agmatine, a bioactive metabolite of arginine. Production, degradation, and functional effects in the kidney of the rat. Journal of Clinical Investigations 97 (1996) 413-420
46. Lu G., Su R.B., Li J., and Qin B.Y. Modulation by α-difluoromethyl-ornithine and aminoguanidine of pain threshold, morphine analgesia and tolerance. European Journal of Pharmacology 478 (2003) 139-144
47. 2-site ligand 2-BFI. Pharmacology Biochemistry and Behavior 75 2 (2003) 427-433
48. Masand P.S., Gupta S., Schwartz T.L., Virk S., Hameed A., and Kaplan D.S. Open-label treatment with citalopram in patients with irritable bowel syndrome: a pilot study. Primary Care Companion Journal of Clinical Psychiatry 7 4 (2005) 162-166
49. Michel M.C., and Ernsberger P. Keeping an eye on the 'I' site: imidazoline-preferring receptors. Trends in Pharmacological Sciences 13 10 (1992) 369-370
50. Michel M.C., and Insel P.A. Are there multiple imidazoline binding sites?. Trends in Pharmacological Sciences 10 9 (1989) 342-344
51. Mukherjee J., and Yang Z.Y. Monoamine oxidase A inhibition by fluoxetine: an in vitro and in vivo study. Synapse 31 4 (1999) 285-289
52. Navarro E., Alonso S.J., Martín F.A., and Castellano M.A. Toxicological and pharmacological effects of d-arginine. Basic Clinical Pharmacology and Toxicology 97 3 (2005) 149-154
53. 15N. American Journal of Physiology Endocrinology and Metabolism 283 (2002) E1123-E1134
54. Olmos G., DeGregorio-Rocasolano N., Paz Regalado M., Gasull T., Assumpcio Boronat M., and Trullas R. Protection by imidazol(ine) drugs and agmatine of glutamate-induced neurotoxicity in cultured cerebellar granule cells through blockade of NMDA receptor. British Journal of Pharmacology 127 6 (1999) 1317-1326
55. Onal A., Delen Y., Ulker S., and Soykan N. Agmatine attenuates neuropathic pain in rats: possible mediation of nitric oxide and noradrenergic activity in the brainstem and cerebellum. Life Sciences 73 (2004) 413-428
56. Otake K., Ruggiero D.A., Regunathan S., Wang H., Milner T.A., and Reis D.J. Regional localization of agmatine in the rat brain: an immunocytochemical study. Brain Research 787 (1998) 1-14
57. Parini A., Moudanos C.G., Pizzinat N., and Lanier S.M. The elusive family of imidazoline binding sites. Trends in Pharmacological Sciences 17 1 (1996) 13-16
58. Paxinos G., and Franklin R.B.J. The Mouse Brain in Stereotaxic Coordinates (1997), Academic Press, San Diego
59. Piletz J.E., Halaris A., and Ernsberger P.R. Psychopharmacology of imidazoline and alpha2-adrenergic receptors: implications for depression. Critical Reviews of Neurobiology 9 1 (1994) 29-66
60. 1-imidazoline binding sites are elevated in depression but not generalized anxiety disorder. Journal of Psychiatry Research 30 3 (1996) 147-168
61. 1-imidazoline binding sites are decreased by two dissimilar antidepressant agents in depressed patients. Journal Psychiatric Research 30 3 (1996) 169-184
62. Piletz J.E., Zhu H., Ordway G., Stockmeier C., Dilly G., Reis D., and Halaris A. Imidazoline receptor proteins are decreased in the hippocampus of individuals with major depression. Biological Psychiatry 48 9 (2000) 910-919
63. Piletz J.E., Baker R., and Halaris A. Platelet imidazoline receptors as state marker of depressive symptomatology. Journal of Psychiatric Research 42 1 (2008) 41-49
64. Porsolt R.D., Bertin A., and Jalfre M. Behavioural despair in mice: a primary screening test for antidepressants. Archives of International Pharmacodynamic Theory 229 (1977) 327-336
65. Raasch W., Regunathan S., Li G., and Reis D.J. Agmatine, the bacterial amine, is widely distributed in mammalian tissues. Life Sciences 56 (1995) 2319-2330
66. 2 specific ligands in vitro. Pharmaceutical and Pharmacological Letters 6 (1996) 42-45
67. Raasch W., Muhle H., and Dominiak P. Modulation of MAO activity by imidazoline and guanidine derivatives. Annals of New York Academy of Sciences 881 (1999) 313-331
68. Raasch W., Schafer U., Chun J., and Dominiak P. Biological significance of agmatine, an endogenous ligand at imidazoline binding sites. British Journal of Pharmacology 133 (2001) 755-780
69. Raddatz R., Parini A., and Lanier S.M. Localization of the imidazoline binding domain on monoamine oxidase B. Molecular Pharmacology 52 4 (1997) 549-553
70. Raddatz R., Savic S.L., Bakthavachalam V., Lesnick J., Jasper J.R., and McGrath C.R. Imidazoline-binding domains monoamine oxidase B and subpopulations of enzyme. Journal of Pharmacology and Experimental Therapeutics 292 3 (2000) 1135-1145
71. Regunathan S. Agmatine: biological role and therapeutic potential in morphine analgesia and dependence. The AAPS Journal 8 5 (2006) E479-E484
72. Regunathan S., and Reis D.J. Stimulation of imidazoline receptors inhibits proliferation of human coronary artery vascular smooth muscle cells. Hypertension 30 (1997) 295-300
73. Regunathan S., and Reis D.J. Characterization of arginine decarboxylase in rat brain and liver: distinction from ornithine decarboxylase. Journal of Neurochemistry 74 (2000) 2201-2208
74. Reis D.J., and Regunathan S. Is agmatine a novel neurotransmitter in brain?. Trends in Pharmacological Sciences 21 (2000) 187-193
75. Remaury A., Raddatz R., Ordener C., Savic S., Shih J.C., and Chen K. Analysis of the pharmacological and molecular heterogeneity of I(2)-imidazoline-binding proteins using monoamine oxidase-deficient mouse models. Molecular Pharmacology 58 5 (2000) 1085-1090
76. Roberts J.C., Grocholski B.M., Kitto K.F., and Fairbanks C.A. Pharmacodynamic and pharmacokinetic studies of agmatine after spinal administration in the mouse. Journal of Pharmacology and Experimental Therapeutics 314 (2005) 1226-1233
77. Rosenfeld H.J., and Roberts J. Arginine decarboxylase from a pseudomonas species. Journal of Bacteriology 125 (1976) 601-607
78. Santos A.R., Gadotti V.M., Oliveira G.L., Tibola D., Paszcuk A.F., Neto A., Spindola H.M., Souza M.M., Rodrigues A.L., and Calixto J.B. Mechanisms involved in the antinociception caused by agmatine in mice. Neuropharmacology 48 7 (2005) 1021-1034
79. 2-imidazoline receptors in the frontal cortex of suicide victims. Annals of New York Academy of Sciences 763 (1995) 520-522
80. Satriano J., Schwartz D., Ishizuka S., Lortie M.J., Thomson S.C., and Gabbai F. Suppression of inducible nitric oxide generation by agmatine aldehyde: beneficial effects in sepsis. Journal of Cellular Physiology 188 3 (2001) 313-320
81. Selamnia M., Mayeur C., Robert V., and Blachicr F. Alpha-difluoromethylornithine (DFMO) as a potent arginase activity inhibitor in human colon carcinoma cells. Biochemical Pharmacology 55 (1998) 1241-1245
82. Sevgi S., Ozek M., and Eroglu L. L-NAME prevents anxiety-like and depression-like behavior in rats exposed to restraint stress. Methods and Findings in Experimental and Clinical Pharmacology 28 2 (2006) 95-99
83. Slotkin T.A., Seidler F.J., Trepanier P.A., Whitmore W.L., Lerea L., Barnes G.A., Weigel S.J., and Bartolome J. Ornithine decarboxylase and polyamines in tissues of the neonatal rat: effects of alphadifluoromethylornithine, a specific, irreversible inhibitor of ornithine decarboxylase. Journal of Pharmacology and Experimental Therapeutics 222 (1982) 741-745
84. Smith J.C.E., and Whitton P.S. Nitric oxide modulates N-methyl-d-aspartate evoked serotonin release in the raphe nuclei and frontal cortex of the freely moving rat. Neuroscience Letters 291 (2000) 5-8
85. Spiacci Jr. A., Kanamaru F., Guimaraes F.S., and Oliveira R.M.W. Nitric oxide mediated anxiolytic-like and antidepressant-like effects in animal models of anxiety and depression. Pharmacology Biochemistry and Behavior 88 (2008) 247-255
86. Stanford S.C. Prozac: panacea or puzzel?. Trends in Pharmacological Sciences 17 (1996) 150-154
87. Steiner M., Steinberg S., Stewart D., Carter D., Berger C., and Reid R. Fluoxetine in the treatment of premenstrual dysphoria. New England Journal of Medicine 332 (1995) 1529-1534
88. Su T.P., Schmidt P.J., Danaceau M.A., Tobin M.B., Rosenstein D.L., Murphy D.L., and Rubinow D.R. Fluoxetine in the treatment of premenstrual dysphoria. Neuropsychopharmacology 16 (1997) 346-356
89. Su R.B., Li J., and Qin B.Y. Effect of l-arginine and anti-l-arginine decarboxylase antibody on morphine analgesia and tolerance. Chinese Journal of Drug Dependence 12 (2003) 97-101
90. Tesson F., Prip-Buus C., Lemoine A., Pegorier J.P., and Parini A. Subcellular distribution of imidazoline-guanidinium-receptive sites in human and rabbit liver. Major localization to the mitochondrial outer membrane. Journal of Biological Chemistry 266 1 (1991) 155-160
91. Tunnicliff G., Schindler N.L., Crites G.J., Goldenberg R., Yochum A., and Malatynska E. The GABA(A) receptor complex as a target for fluoxetine action. Neurochemical Research 24 10 (1999) 1271-1276
92. Ugale R.R., Hirani K., Morelli M., and Chopde C.T. Role of neuroactive steroid allopregnanolone in antipsychotic-like action of olanzapine in rodents. Neuropsychopharmacology 29 (2004) 1597-1609
93. Velloso N.A., Dalmolin G.D., Fonini G., Gindri Sinhorin V.D., Ferreira da Silveira A., Rubin M.A., and Mello C.F. Spermine attenuates behavioral and biochemical alterations induced by quinolinic acid in the striatum of rats. Brain Research 1198 (2008) 107-114
94. Wang H., Regunathan S., Youngson C., and BramwellReis D.J. An antibody to agmatine localizes the amine in bovine adrenal chromaffin cells. Neuroscience Letters 183 (1995) 17-21
95. Wang D., An S.C., and Zhang X. Prevention of chronic stress-induced depression-like behavior by inducible nitric oxide inhibitor. Neuroscience Letters 433 1 (2008) 59-64
96. Wegener G., Volke V., and Rosenberg R. Endogenous nitric oxide decreases hippocampal levels of serotonin and dopamine in vivo. British Journal of Pharmacology 130 (2000) 575-580
97. Wu N., Su R.B., and Li J. Agmatine and imidazoline receptors: their role in opioid anlagesis, tolerance and dependence. Cell and Molecular Neurobiology 28 5 (2007) 629-641
98. Yang X.C., and Reis D.J. Agmatine selectively blocks the NMDA subclass of glutamate receptor channels in cultured mouse hippocampal neurons. Journal of Pharmacology and Experimental Therapeutics 288 (1999) 544-549
99. Yildiz F., Erden B.F., Ulak G., Utkan T., and Gacar N. Antidepressant-like effect of 7-nitroindazole in the forced swimming test in rats. Psychopharmacology (Berl) 149 1 (2000) 41-44
100. Zeidan M.P., Zomkowski A.D.E., Rosa A.O., Rodrigues A.L.S., and Gabilan N.H. Evidence for imidazoline receptors involvement in the agmatine antidepressant-like effect in the forced swimming test. European Journal of Pharmacology 565 (2007) 125-131
101. Zhao S., Feng Y., LeBlanc M.H., Piletz J.E., and Liu Y.M. Quantitation of agmatine by liquid chromatography with laser-induced fluorescence detection. Analytica Chimica Acta 470 (2002) 155-161
102. Zhu H., Halaris A., Madakasira S., Pazzaglia P., Goldman N., and De Vane C.L. Effect of bupropion on immunodensity of putative imidazoline receptors on platelets of depressed patients. Journal of Psychiatric Research 33 (1999) 323-333
103. Zhu M.Y., Iyo A., Piletz J.E., and Regunathan S. Expression of human arginine decarboxylase, the biosynthetic enzyme for agmatine. Biochim Biophys Acta 1670 (2004) 156-164
104. Zhu M.Y., Wang W.P., Huang J., Feng Y.Z., and Regunathan S. Chronic treatment with glucocorticoid alters rat hippocampal and prefrontal cortical morphology in parallel with endogenous agmatine and arginine decarboxylase levels. Journal of Neurochemistry 103 (2007) 1811-1820
105. Zhu M.Y., Wang W.P., Huang J., Feng Y.Z., Regunathan S., and Bissette G. Repeated immobilization stress alters rat hippocampal and prefrontal cortical morphology in parallel with endogenous agmatine and arginine decarboxylase levels. Neurochemistry International 53 (2008) 346-354
106. Zomkowski A.D., Hammes L., Lin J., Calixto J.B., Santos A.R.S., and Rodrigues A.L.S. Agmatine produces antidepressant-like effects in two models of depression in mice. Neuroreport 13 (2002) 387-391
107. Zomkowski A., Rosa A., Lin J., Santos A.R., Calixto J.B., and Rodrigues A. Evidence for serotonin receptor subtypes involvement in agmatine antidepressant like-effect in the mouse forced swimming test. Brain Research 1023 2 (2004) 253-263